Dispatch Bio

Day 1 at #ASGCT2026! Come view our poster on Thursday to learn more about our SEND (Synthetic Efficacy eNableD) T cell armoring strategy, an approach designed to overcome the limitations of supportive cytokine signals in the tumor microenvironment. Preclinical data demonstrate strong anti-tumor activity with a clean safety profile in solid tumor models, representing a potentially best-in-class breakthrough for the treatment of cancer that could be broadly applicable across engineered T cell approaches. We look forward to connecting with the gene & cell therapy community.

Our name, explained. The name “Dispatch” reflects our dual approach to precision medicine, using our first-in-class Flare platform. First, we dispatch a tumor-specific virus to deliver a Flare antigen. Then, that antigen acts as a beacon to target therapeutics (or "dispatch") to find and clear marked #cancer cells with unmatched accuracy. Our science is embedded in our name and our approach to engineering a universal treatment across solid tumors.

We’re proud to see our co-founder Carl June and founding chairman Jeff Marrazzo recognized as Disruptors of the Year at The Philadelphia Citizen’s 2026 Citizen of the Year Awards, in honor of their instrumental contributions to founding Dispatch. This annual program highlights individuals driving meaningful change by bringing together leaders committed to strengthening the Philadelphia region’s future. Carl and Jeff’s work reflects a growing life sciences ecosystem where breakthrough science can be translated into real impact for patients. Congratulations to both and to all of this year’s honorees on the progress they are making for the Philadelphia community. Read the event recap and check out some photos in the article below. https://lnkd.in/gSRVyinZ

We’re looking forward to #ASGCT2026 this May, where we will present new preclinical data supporting our SEND (Synthetic Efficacy eNableD) T cell armoring strategy. SEND is designed to enable simultaneous activation of multiple T cell signaling pathways to enhance T cell efficacy and durability. We believe SEND has the potential to optimize safety and efficacy profiles of a multitude of immunotherapy treatments, with broad applicability across engineered T cell approaches, including autologous CAR T therapies, in vivo CAR T approaches, TCR-based therapies, and others. Learn more here: https://lnkd.in/gTf-cBzK

We’re proud to be part of the Parker Institute for Cancer Immunotherapy network and share in their mission to advance scientific discovery into therapeutic progress. Here’s to continuing to work together to improve outcomes for people with #cancer. Read more below.

We’re thrilled to share that our co-founder and Chief Platform Officer Lexus Johnson, PhD has been included in this year’s Philadelphia Business Journal's 40 Under 40. This award reflects Lex’s leadership and continued commitment to advancing Dispatch’s work to improve outcomes for patients with solid tumors, while contributing Philadelphia’s growing life sciences community, and advancing the biotech industry as a whole. Congratulations to all of this year’s honorees. View more info here: https://lnkd.in/d6kCq7D6

We’re pleased to share that Chris Wiwi has been promoted to Chief Technical Officer at Dispatch. Since joining as one of our early hires, Chris has built and led our technical operations organization spanning CMC development and manufacturing. His leadership and disciplined execution have helped position Dispatch for our next stage as we enter clinical development, and he will continue guiding these efforts in his new role. Congratulations, Chris, on this well-deserved promotion!

Our Chief Scientific Officer, Barbra Sasu, will present at the 2026 Society for Immunotherapy of Cancer (SITC) Spring Scientific - Next-gen Cell Therapies, T cell Engagers, and Combinations meeting to discuss how synthetic antigen strategies may enable universal immunotherapies across solid tumors, an approach designed to help address longstanding targeting and resistance challenges in #immunotherapy. We look forward to engaging with the immuno-oncology community as we continue to work toward improving treatment options for patients with solid tumors.

We’re excited to share that we were recognized as the Emerging Company of the Year at the Life Sciences Pennsylvania 2026 Annual Dinner & Showcase. This recognition celebrates companies demonstrating meaningful progress while contributing to the strength of Pennsylvania’s life sciences community. For our team, it reflects the persistence, collaboration, and determination required to advance new approaches designed to overcome the targeting and resistance challenges that have historically limited immunotherapy across solid tumors. We’re grateful to Life Sciences Pennsylvania and fortunate to be part of a community committed to advancing scientific innovation and patient impact. Take a look at a few photos from the evening below.

This week, we had the chance to share our story with the MBC BioLabs community in San Francisco. Our CEO Sabah Öney, alongside co-founders Lexus Johnson, PhD, Chief Platform Officer, and Ray Liu, PhD, Head of Synthetic Biology, discussed how we’re advancing our first-in-class Flare platform that’s designed to overcome the targeting and resistance challenges that have historically limited the effectiveness of immunotherapy treatments in solid tumors. Thank you to MBC BioLabs for hosting such a thoughtful gathering and for being an important collaborator in our journey. We’re grateful to engage with the broader community and to share the work our team is advancing as we continue building Dispatch.